ProCE Banner Activity

Phase I Study of KIT D816V Inhibitor Avapritinib (BLU-285) in Advanced Systemic Mastocytosis

Slideset Download
Conference Coverage
Avapritinib was well tolerated and safe across several dose levels with an ORR of 72% by IWG-MRT-ECNM criteria.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology